Evidence map›Paper›PMID 42311260›Full record

ArticleFrontiers in oncology2026

Complete radiographic response to immunotherapy in a patient with metastatic anaplastic thyroid cancer - a case report and review of the literature.

Monika Mierzejewska, Lin Akily, William Karlsen, Jacek Teodorczyk, Bartłomiej Tomasik, Jacek Rutkowski, Piotr Wiśniewski, Maciej Śledziński, Karolina Markiet, Jolanta Szade and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Monika MierzejewskaDepartment of Nuclear Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Lin AkilyDepartment of Internal Medicine, Ljungby Hospital, Ljungby, Sweden.
William KarlsenDepartment of Internal Medicine, Visby Hospital, Visby, Sweden.
Jacek TeodorczykDepartment of Nuclear Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Bartłomiej TomasikDepartment of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.
Jacek RutkowskiDepartment of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.
Piotr WiśniewskiDepartment of Endocrinology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland.
Maciej ŚledzińskiDepartment of General, Endocrine and Transplant Surgery, Medical University of Gdańsk, Gdańsk, Poland.
Karolina Markiet2nd Division of Radiology, Medical University of Gdańsk, Gdańsk, Poland.
Jolanta SzadeDepartment of Pathomorphology, Medical University of Gdańsk, Gdańsk, Poland.
Renata ZauchaDepartment of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.
Wojciech CytawaDepartment of Nuclear Medicine, Medical University of Gdańsk, Gdańsk, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here we present the case of a 76-year-old female with anaplastic thyroid cancer (ATC), stage pT3bN0, who was initially treated with total thyroidectomy followed by adjuvant radiotherapy after non-radical (R1) surgery. Three months after initial treatment, the disease rapidly progressed and disseminated to the lungs, causing significant pulmonary insufficiency. Due to high PD-L1 expression of the tumor, the patient was offered off-label immunotherapy with an immune checkpoint inhibitor (ICI) (nivolumab monotherapy) and demonstrated a remarkable radiographic and clinical response, achieving prolonged progression-free survival (12 months) and overall survival (18 months). ICIs may represent a valuable therapeutic option for patients with metastatic ATC exhibiting high PD-L1 expression. The presented case report and literature review underscore the need for clinical trials to confirm the efficacy of immunotherapy in ATC.

Indexed as

anaplastic thyroid cancercomplete responseimmune checkpoint inhibitorimmune-related adverse eventimmunotherapy

Identifiers

PMID42311260
PMCPMC13269043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.